Malik Fady Ibraham, EVP of Research & Development, has filed 59 Form 4 transactions across two companies, with a clear sell-side bias. His total open-market sales amount to $5,362,465.34, while he has recorded zero open-market purchases. The recent activity, spanning April through October 2026, shows a consistent pattern of paired option exercises and sales in Cytokinetics (CYTK). Each exercise is valued at $27,300, followed by a sale of roughly $215,000 to $303,000. The most recent sale occurred on October 6, 2026, at $214,830, paired with an exercise of the same date. Prior sales on September 22 and September 8 brought in $239,015 and $264,110, respectively.
The transaction cadence is regular, with sales occurring roughly every two to three weeks. August 18 produced $265,370, July 21 yielded $282,065, and July 7 generated $303,170, the largest single sale in the window. June 23 and June 9 sales totaled $278,285 and $237,930. May saw sales of $264,915 on May 19 and $270,795 on May 5. April 21 brought $229,915, and April 7 closed the period with a smaller $64,750 sale. The April 7 sale had no corresponding exercise, unlike the others.
Ibraham also holds equity in Rocket Pharmaceuticals (RCKT), where he received two grants on June 18, 2026, both valued at $0. These are compensation awards, not purchases. Across all filings, there are no open-market buys, no sales back to the issuer, and no gifts. The CYTK sales are all paired with option exercises, meaning the shares sold were acquired through exercise rather than bought on the open market. The total sell value of $5.36 million, combined with zero buy value, shows a consistent disposition of CYTK shares over the six-month period.
AI-assisted summary